Calgary biotech moving to Vancouver, going public

A new Calgary-based biotech focused on diabetes and hypertension will go public later this month in a reverse takeover with a local junior mining company ...
Xortx founder Allen Davidoff

A new Calgary-based biotech focused on diabetes and hypertension will go public later this month in a reverse takeover with a local junior mining company and relocate to Vancouver.

Xortx Pharma Corp. – a biotech startup whose management team has ties with Vancouver’s Cardiome Pharma Corp. (TSX:COM) – is focused on treating hypertension, insulin resistance and diabetes-related kidney disease with a reformulated drug – Xorlo – a variation of which has been used to successfully treat gout.

The company hopes to raise $6 million to $9 million through a reverse takeover involving African Queen Mines Ltd. (TSX-V: AQ) in late June or early July. The money is to help pay for clinical trials.

Xortx founder Allen Davidoff said he plans to relocate the company to Vancouver, in part because that is where African Queen is located, although Davidoff also has ties here.

“Vancouver has a wealth of life science professionals, capital market folks who understand the life sciences theme and a biotech research infrastructure that’s very attractive,” Davidoff said.

Davidoff was a senior scientist with Cardiome before he moved to Calgary and founded his own company, Stem Cell Therapeutics Corp. – now Trillium Therapeutics Inc. (TSX: SSS).

Co-founder Alan Moore is also a former Cardiome scientist, as are two other members of the Xortx management team.

Xorlo is a reformulated drug based on the primary chemistry of a drug that is already approved for gout.

One of the things gout has in common with hypertension, insulin resistance and diabetes-related kidney disease is high levels of serum uric acid, Davidoff said. It is believed that Xorlo can be used to lower those levels to treat three types of diseases. However, the company will focus first on hypertension.

nbennett@biv.com

@nbennett_biv

comments powered by Disqus

More from Technology

Corvus Energy’s marine power focus pays dividends

Richmond battery maker doubled its revenue between fiscal 2015 and 2016, topping BIV's list of fastest-growing companies

Read Article

BIV on Global BC August 25, 2016: Snapchat lawsuit

Read Article

Vancouver tech company targets nanomedicine niche

Precision NanoSystems develops a faster, cheaper way to produce nanoparticles

Read Article

Obamacare gives local health tech a helping hand

Increased screening in U.S. helps accelerate Vancouver company’s growth

Read Article

Making the business case for corporate data-driven decisions

Decision analytics company applies deep data to challenges faced by energy, water and government sectors around the world

Read Article

Subscribe to our mailing lists

* indicates required

Newsletters

* You can modify your newsletter subscriptions at the bottom of any newsletter you receive.
×